Routine blood biomarkers associated with clinical response to tralokinumab in patients with atopic dermatitis: a 48-week real-world study in Japan
Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki et autres
Tralokinumab is effective for atopic dermatitis (AD), however, biomarkers reflecting its therapeutic effects have not been fully established. To evaluate whether blood biomarkers are associated with clinical response to tralokinumab during 48 weeks of treatment for AD. We conducted a prospective two-centre …
jp (code pays fourni par la source)
0 citations
European Journal of Dermatology